1. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
- Author
-
Hao Wu, Danlei Mou, Lei Xu, Bin Zhang, Yufeng Zhang, Yulin Liu, Hu Chen, Liangfu Xie, Jun Xu, Hongmei Ning, Longteng Wang, Long Zhao, Tingting Liu, Bin Su, Tong Zhang, Kai Deng, Xiaobao Wang, Cheng Li, Hongkui Deng, Lifeng Liu, Liangding Hu, Xiaofan Lu, and Jun Wang
- Subjects
Adult ,Male ,Receptors, CCR5 ,Genetic enhancement ,medicine.medical_treatment ,Context (language use) ,HIV Infections ,Hematopoietic stem cell transplantation ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Genome editing ,Acute lymphocytic leukemia ,Medicine ,CRISPR ,Humans ,030212 general & internal medicine ,Gene Editing ,business.industry ,Hematopoietic Stem Cell Transplantation ,General Medicine ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Viral Load ,medicine.disease ,Hematopoietic Stem Cells ,Virology ,Blood Cell Count ,CD4 Lymphocyte Count ,Anti-Retroviral Agents ,HIV-1 ,Stem cell ,CRISPR-Cas Systems ,business ,Viral load - Abstract
Summary The safety of CRISPR (clustered regularly interspaced short palindromic repeats)–based genome editing in the context of human gene therapy is largely unknown. CCR5 is a reasonable but not a...
- Published
- 2019